At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRVO CervoMed
Market Closed 04-24 16:00:00 EDT
3.88
+0.03
+0.78%
盘后3.88
+0.000.00%
19:55 EDT
High3.95Low3.79Vol31.43K
Open3.88D1 Closing3.85Amplitude4.16%
Mkt Cap35.90MTradable Cap19.15MTotal Shares9.25M
T/O121.96KT/O Rate0.64%Tradable Shares4.93M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cochlear (OtherCHEOF), CervoMed (CRVO) and Community Health (CYH)
TIPRANKS  ·  04-24 17:01
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cochlear (OtherCHEOF), CervoMed (CRVO) and Community Health (CYH)
CervoMed Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Dow Jones  ·  04-23 20:02
CervoMed Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Neflamapimod’s MRI and Connectivity Data Support Disease‑Modifying Potential in Dementia With Lewy Bodies and Underscore Buy Rating on CervoMed
TIPRANKS  ·  04-23 19:15
Neflamapimod’s MRI and Connectivity Data Support Disease‑Modifying Potential in Dementia With Lewy Bodies and Underscore Buy Rating on CervoMed
CervoMed presents neflamapimod MRI data
TIPRANKS  ·  04-22
CervoMed presents neflamapimod MRI data
CervoMed says neflamapimod boosts right basal forebrain volume in Lewy body dementia trial
Reuters  ·  04-22
CervoMed says neflamapimod boosts right basal forebrain volume in Lewy body dementia trial
Roth MKM Remains a Buy on CervoMed (CRVO)
TIPRANKS  ·  04-15
Roth MKM Remains a Buy on CervoMed (CRVO)
CervoMed Is Maintained at Buy by D. Boral Capital
Dow Jones  ·  04-08
CervoMed Is Maintained at Buy by D. Boral Capital
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
TIPRANKS  ·  04-08
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
CervoMed says new Phase 2b MRI analysis supports neflamapimod slowing DLB progression
Reuters  ·  04-07
CervoMed says new Phase 2b MRI analysis supports neflamapimod slowing DLB progression
CervoMed (CRVO) Gets a Buy from JonesTrading
TIPRANKS  ·  04-07
CervoMed (CRVO) Gets a Buy from JonesTrading
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
TIPRANKS  ·  03-24
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
Cervomed Inc. Publishes Presentation Factsheet
Reuters  ·  03-24
Cervomed Inc. Publishes Presentation Factsheet
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
TIPRANKS  ·  03-20
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
CervoMed Is Maintained at Buy by D. Boral Capital
Dow Jones  ·  03-20
CervoMed Is Maintained at Buy by D. Boral Capital
BUZZ-U.S. STOCKS ON THE MOVE-Rivian,  Biohaven, CervoMed
Reuters  ·  03-19
BUZZ-U.S. STOCKS ON THE MOVE-Rivian,  Biohaven, CervoMed
CervoMed’s neflamapimod shows efficacy in dementia with DLB
TIPRANKS  ·  03-19
CervoMed’s neflamapimod shows efficacy in dementia with DLB
BRIEF-CervoMed Announces New Data At The Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’S Positive Effects In Dementia With Lewy Bodies (DLB) In Patients Without Alzheimer’S Disease Co-Pathology
Reuters  ·  03-19
BRIEF-CervoMed Announces New Data At The Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’S Positive Effects In Dementia With Lewy Bodies (DLB) In Patients Without Alzheimer’S Disease Co-Pathology
CervoMed reports Phase 2b neflamapimod benefit in DLB patients with plasma pTau181 below 21 pg/mL
Reuters  ·  03-19
CervoMed reports Phase 2b neflamapimod benefit in DLB patients with plasma pTau181 below 21 pg/mL
CervoMed Announces New Data at the Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’s Positive Effects in Dementia With Lewy Bodies (Dlb) in Patients Without Alzheimer’s Disease Co-Pathology
THOMSON REUTERS  ·  03-19
CervoMed Announces New Data at the Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’s Positive Effects in Dementia With Lewy Bodies (Dlb) in Patients Without Alzheimer’s Disease Co-Pathology
CervoMed Is Maintained at Buy by Chardan Capital
Dow Jones  ·  03-18
CervoMed Is Maintained at Buy by Chardan Capital

Introduction

Company Name.
CervoMed
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Issue price:
--